This is a working overview of ghrelin receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-15 and is reviewed periodically as new material appears.
Ipamorelin 是一种合成五肽,在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路,但并非天然激素。早期药理学研究显示,它可刺激垂体释放生长激素,而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。
在机制层面,ipamorelin 与生长激素促分泌受体 1a 型结合,该受体也介导胃饥饿素的多种效应。受体激活后,细胞内信号促进生长激素从垂体前叶释放。由于对促肾上腺皮质激素和皮质醇的刺激较弱,它被视为选择性较高的促分泌剂。这种选择性在动物模型和少量人体研究中被观察到,但人体数据仍然有限。
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
| Property | Value | Notes |
|---|---|---|
| 分子式 | C38H49N9O5 | 五肽,含非天然氨基酸残基 |
| 分子量 | 711.85 g/mol | 理论值,盐形式可能略有差异 |
| 外观 | 白色至类白色粉末 | 冻干粉常见 |
| 溶解性 | 易溶于水 | 也可溶于部分极性有机溶剂 |
| 储存条件 | -20°C,干燥避光 | 长期保存通常推荐 |
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Mass spectrometry confirms identity and reveals structural deviations that chromatography alone can miss. Positive-mode electrospray ionisation generally yields multiply charged ions whose deconvoluted mass is checked against the theoretical value. Amino acid analysis, and enzymatic digestion with subsequent fragment mapping, provide independent confirmation of sequence and of the terminal amide. Analysts take care to separate the target from deletion sequences, which may differ by one residue and therefore by only a small mass increment.
The lyophilised solid is normally held at -20 °C or colder, shielded from light and moisture. Stability in that state is measured in years, although shelf life depends on residual water content and the container seal. Once dissolved, the peptide is more fragile: aqueous solutions are commonly kept at 2-8 °C and used within days to weeks, and repeated freeze-thaw cycling is avoided. Strongly acidic or basic conditions accelerate hydrolysis, and prolonged exposure to them can strip the terminal amide.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
Verification of identity and purity relies on analytical methods used across peptide chemistry. Reverse-phase high-performance liquid chromatography separates components by hydrophobicity and provides a purity estimate. Mass spectrometry confirms molecular mass and helps detect modifications. Together these techniques give complementary information about whether a sample matches its expected structure. Results depend on method parameters and reference standards, so reported purity values are meaningful only when the analytical conditions are stated. Consistency between laboratories requires comparable protocols and well-characterized reference materials.
Peptides such as ipamorelin are subject to chemical and physical degradation. Hydrolysis of peptide bonds, oxidation of susceptible residues, and aggregation are common pathways that reduce purity over time. The rate of these processes depends on temperature, moisture, pH, and the number of freeze-thaw cycles a sample undergoes. Because the compound is typically handled as a lyophilized powder, controlling moisture during storage is a central concern. Degradation products can be detected with separation techniques that resolve the parent peptide from related impurities.
Interpreting this as a sign that Smith intended to declare independence if a majority backed it in the referendum, Wilson wrote a stiff letter to Smith on 25 October, warning him of the consequences of UDI, and demanding "a categorical assurance forthwith that no attempt at a unilateral declaration of independence on your part will be made". Smith expressed confusion as to what he had done to provoke this, and ignored it. When the indaba ended on 26 October, the chiefs and headmen returned a unanimous decision to support the government's stand for independence under the 1961 constitution, attesting in their report that "people who live far away do not understand the problems of our country". This verdict was rejected by the nationalist movement on the grounds that the chiefs received governmental salaries; the chiefs countered that the black MPs in parliamentary opposition also received such salaries, but still opposed the government. Malvern, who was becoming perturbed by the RF's actions, dismissed the indaba as a "swindle", asserting that the chiefs no longer had any real power; the British simply ignored the whole exercise. On 27 October, Wilson released a firm statement regarding Britain's intended response to UDI, warning that Rhodesia's economic and political ties with Britain, the Commonwealth and most of the world would be immediately severed amid a campaign of sanctions if Smith's government went ahead with UDI.
== Other hydroxylations == The function of the remainder of the hydroxylated E2 metabolites (6α-, 6β-, 7α-, 12β-, 15α-, 15β-, and 16β-OHE2) remain to be elucidated. Some of these metabolites, such as 15α-OHE2, are excreted in relatively large amounts in pregnant women, possibly serving as an indicator of good fetal health.
==== Warp Drive Bio ==== In 2012, Verdine founded Warp Drive Bio with cofounders George Church and James Wells. The company maps the genomes of soil-dwelling microbes in the search for potential treatments for drug-resistant ailments. In 2013, Verdine became full-time CEO of Warp Drive Bio, then handed the CEO position to Lawrence Reid in 2016 in order to found two new startups, FogPharma and LifeMine.
Most Moluccans in northern Maluku (present-day province of North Maluku) are Muslim. Central and southern Maluku (present-day province of Maluku) have approximately equal numbers of Muslims and Christians. There is significant number of native Hindus (Tanimbar Kei people) living in the Kei Islands, which is a predominantly Catholic region. This is because, according to oral traditions, their ancestors came from Bal (Bali) during the Majapahit era. Additionally, they practice local customary law called Larvul Ngabal (transl. "red blood and spear from Bali"). The most common religion amongst Moluccans in the Netherlands is Protestantism, followed by Islam.
Sources: en.wikipedia.org
== Production and use == Nitrilotriacetic acid is commercially available as the free acid and as the sodium salt. It is produced from ammonia, formaldehyde, and sodium cyanide or hydrogen cyanide. NTA is also cogenerated as an impurity in the synthesis of EDTA, arising from reactions of the ammonia coproduct. Older routes to NTA included alkylation of ammonia with chloroacetic acid and oxidation of triethanolamine.
==== Broadcast ==== Raleigh is part of the Raleigh-Durham-Fayetteville Designated Market Area, the 24th largest broadcast television market in the United States. The following stations are licensed to Raleigh and/or have significant operations and viewers in the city:
==== MeSH D06.472.334 – gonadal hormones ==== MeSH D06.472.334.500 – activins MeSH D06.472.334.500.500 – inhibin-beta subunits MeSH D06.472.334.734 – corpus luteum hormones MeSH D06.472.334.734.623 – progesterone MeSH D06.472.334.734.769 – relaxin MeSH D06.472.334.851 – gonadal steroid hormones MeSH D06.472.334.851.437 – estradiol congeners MeSH D06.472.334.851.437.249 – equilenin MeSH D06.472.334.851.437.374 – equilin MeSH D06.472.334.851.437.500 – estradiol MeSH D06.472.334.851.437.750 – estriol MeSH D06.472.334.851.437.750.320 – estetrol MeSH D06.472.334.851.437.968 – estrogenic steroids, alkylated MeSH D06.472.334.851.437.968.500 – ethinyl estradiol MeSH D06.472.334.851.437.968.500.250 – ethinyl estradiol-norgestrel combination MeSH D06.472.334.851.437.968.500.500 – mestranol MeSH D06.472.334.851.437.968.500.750 – quinestrol MeSH D06.472.334.851.437.984 – estrogens, catechol MeSH D06.472.334.851.437.984.350 – hydroxyestrones MeSH D06.472.334.851.437.988 – estrogens, conjugated (usp) MeSH D06.472.334.851.437.994 – estrogens, esterified (usp) MeSH D06.472.334.851.437.996 – estrone MeSH D06.472.334.851.687 – progesterone congeners MeSH D06.472.334.851.687.500 – pregnenolone MeSH D06.472.334.851.687.500.500 – 17-alpha-hydroxypregnenolone MeSH D06.472.334.851.687.750 – progesterone MeSH D06.472.334.851.687.750.074 – 20-alpha-dihydroprogesterone MeSH D06.472.334.851.687.750.099 – 5-alpha-dihydroprogesterone MeSH D06.472.334.851.687.750.478 – hydroxyprogesterones MeSH D06.472.334.851.687.750.478.400 – 17-alpha-hydroxyprogesterone MeSH D06.472.334.851.687.750.478.400.500 – pregnanetriol MeSH D06.472.334.851.687.750.739 – pregnanediol MeSH D06.472.334.851.968 – testosterone congeners MeSH D06.472.334.851.968.500 – androstane-3,17-diol MeSH D06.472.334.851.968.750 – androstenediol MeSH D06.472.334.851.968.875 – androstenedione MeSH D06.472.334.851.968.937 – androsterone MeSH D06.472.334.851.968.952 – dehydroepiandrosterone MeSH D06.472.334.851.968.952.300 – dehydroepiandrosterone sulfate MeSH D06.472.334.851.968.964 – dihydrotestosterone MeSH D06.472.334.851.968.968 – etiocholanolone MeSH D06.472.334.851.968.976 – nandrolone MeSH D06.472.334.851.968.984 – testosterone MeSH D06.472.334.851.968.984.500 – epitestosterone MeSH D06.472.334.851.968.984.750 – testosterone propionate MeSH D06.472.334.968 – inhibins MeSH D06.472.334.968.500 – inhibin-beta subunits MeSH D06.472.334.984 – testicular hormones
== Contraindications == The only absolute contraindication to the use of ivermectin is hypersensitivity to the active ingredient or any component of the formulation. In children under the age of five or those who weigh less than 15 kilograms (33 pounds), there is limited data regarding the efficacy or safety of ivermectin, though the available data demonstrate few adverse effects. However, the American Academy of Pediatrics cautions against use of ivermectin in such patients, as the blood–brain barrier is less developed, and thus there may be an increased risk of particular CNS side effects such as encephalopathy, ataxia, coma, or death. The American Academy of Family Physicians also recommends against use in these patients, given a lack of sufficient data to prove drug safety. Ivermectin is secreted in very low concentration in breast milk. It remains unclear if ivermectin is safe during pregnancy.
Severe aortic stenosis with or without symptoms Aortic regurgitation with NYHA functional class III-IV symptoms Mitral stenosis with NYHA functional class II-IV symptoms Mitral regurgitation with NYHA functional class III-IV symptoms Aortic and/or mitral valve disease resulting in severe pulmonary hypertension (pulmonary pressure greater than 75% of systemic pressures) Aortic and/or mitral valve disease with severe LV dysfunction (EF less than 0.40) Mechanical prosthetic valve requiring anticoagulation Marfan syndrome with or without aortic regurgitation
Sources: en.wikipedia.org
l-Histidine is an essential amino acid that is not synthesized de novo in humans. Humans and other animals must ingest histidine or histidine-containing proteins. The biosynthesis of histidine has been widely studied in prokaryotes such as E. coli. Histidine synthesis in E. coli involves eight gene products (His1, 2, 3, 4, 5, 6, 7, and 8) and it occurs in ten steps. This is possible because a single gene product has the ability to catalyze more than one reaction. For example, as shown in the pathway, His4 catalyzes four different steps in the pathway. Histidine is synthesized from phosphoribosyl pyrophosphate (PRPP), which is made from ribose-5-phosphate by ribose-phosphate diphosphokinase in the pentose phosphate pathway. The first reaction of histidine biosynthesis is the condensation of PRPP and adenosine triphosphate (ATP) by the enzyme ATP-phosphoribosyl transferase. ATP-phosphoribosyl transferase is indicated by His1 in the image. His4 gene product then hydrolyzes the product of the condensation, phosphoribosyl-ATP, producing phosphoribosyl-AMP (PRAMP), which is an irreversible step. His4 then catalyzes the formation of phosphoribosylformiminoAICAR-phosphate, which is then converted to phosphoribulosylformimino-AICAR-P by the His6 gene product. His7 splits phosphoribulosylformimino-AICAR-P to form d-erythro-imidazole-glycerol-phosphate. After, His3 forms imidazole acetol-phosphate releasing water. His5 then makes l-histidinol-phosphate, which is then hydrolyzed by His2 making histidinol.
=== Chromatography === Alkylamides can be used as chromatographic stationary phases. Those phases have been investigated for the separation of oligonucleotides. Ion-pair reverse-phase high-performance liquid chromatography is used to separate and analyse the oligonucleotides after automated synthesis.
In addition, a direct joining of ribose, a nucleobase, and phosphate to make a ribonucleotide (the building block of RNA) is not currently chemically feasible. Alternative prebiotic mechanisms have been proposed including cyanosulfidic prebiotic chemistries.
{\displaystyle {\begin{aligned}x:\ &\rho \left({\partial _{t}u_{x}}+u_{x}\,{\partial _{x}u_{x}}+u_{y}\,{\partial _{y}u_{x}}+u_{z}\,{\partial _{z}u_{x}}\right)\\&\quad =-\partial _{x}p+\mu \left({\partial _{x}^{2}u_{x}}+{\partial _{y}^{2}u_{x}}+{\partial _{z}^{2}u_{x}}\right)+{\frac {1}{3}}\mu \ \partial _{x}\left({\partial _{x}u_{x}}+{\partial _{y}u_{y}}+{\partial _{z}u_{z}}\right)+\rho g_{x}\\\end{aligned}}}
Sources: en.wikipedia.org
不是。它属于人工合成的五肽,设计上模拟胃饥饿素受体的部分作用,但不存在于人体天然激素谱中。
生长激素释放激素通过其专用受体起作用,而 ipamorelin 主要作用于胃饥饿素受体。两者可影响生长激素释放,但信号通路和下游效应并不相同。
研究多集中在生长激素释放的急性调节、受体选择性以及不同给药方式下的药代动力学。临床终点研究数量有限,长期结局尚不明确。
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.